Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GABRP | O00591 | 3/20 | 0.47 |
| ▸ | GABRD | O14764 | 3/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.47 |
| ▸ | GABRE | P78334 | 3/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11721563 | 0.83 | SMN1; SMN2 (0.56) | HPGDHTTKDM4EGAAALDH1A1 | |
| SCHEMBL13313461 | 0.81 | HPGD (0.46) | HPGDHTTKDM4EKMT2AGABRP | |
| SCHEMBL12272538 | 0.81 | NNMT (0.46) | HPGDHTTKDM4EKMT2AGABRP | |
| SCHEMBL8546294 | 0.81 | HPGD (0.59) | HPGDHTTKDM4EKMT2AGABRP | |
| SCHEMBL1540141 | 0.81 | HPGD (0.59) | HPGDHTTKDM4EKMT2AGABRP | |
| SCHEMBL5884203 | 0.81 | HPGD (0.46) | HPGDHTTKDM4EKMT2AGABRP | |
| SCHEMBL27923036 | 0.79 | HPGD (0.44) | HPGDHTTKDM4EKMT2AGABRP | |
| SCHEMBL4274478 | 0.79 | HPGD (0.44) | HPGDHTTKDM4EKMT2AGABRP | |
| SCHEMBL1759179 | 0.79 | GABRP (0.52) | HPGDKDM4EKMT2AGABRPGABRD | |
| SCHEMBL24868589 | 0.79 | HPGD (0.58) | HPGDHTTKDM4EKMT2AGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164918-A | Synthesis method of 2, 4-dimethyl-5-aminopyrimidine | 南通大学 | 2024-06-11 | — | — | CN | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-12583849-B2 | KCNT1 inhibitors and methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4692069-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4110317-B1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| CN-118164918-A | Synthesis method of 2, 4-dimethyl-5-aminopyrimidine | 南通大学 | 2024-06-11 | — | — | CN | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-4110317-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115443129-A | KCNT1 inhibitors and methods of use | 普拉西斯精密医药公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20040063946-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1364949-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-6387930-B1 | ANTIARTHRITIC AGENTS; ANTIALLERGENS; SKIN DISORDERS; INFLAMMATORY BOWEL DISORDERS | SCHERING CORPORATION | 2002-05-14 | — | — | US | disclosed |
| EP-0112617-B1 | PROCESS FOR THE EXTRACTION OF METAL VALUES AND NOVEL METAL EXTRACTANTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-12-30 | — | — | EP | disclosed |
| US-4581220-A | CURED RESIDUE OF ZIRCONIUM SOLUTION | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1986-04-08 | — | — | US | disclosed |
| US-4576815-A | Process for the extraction of metal values and novel metal extractants | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1986-03-18 | — | — | US | disclosed |
| EP-0112617-A1 | Process for the extraction of metal values and novel metal extractants | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | KCNT1, SCN1A, KCNT2 | HPGD 2282/4885HTT 227/4885KDM4E 2512/4885 |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | HPGD 2270/4885HTT 141/4885KDM4E 1355/4885 |
| US-20040063946-A1 | Jnk inhibitor | MAPK1, MAPK7, MAP3K7 | HPGD 1987/4885HTT 4703/4885KDM4E 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.